Literature DB >> 22346501

Once-daily aminoglycoside dosing: A new look at an old drug.

J Conly1, W Gold, S Shafran.   

Abstract

Entities:  

Year:  1994        PMID： 22346501      PMCID： PMC3250833          DOI： 10.1155/1994/796138

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN： 1180-2332


× No keyword cloud information.
  12 in total

Review 1.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Modification of experimental aminoglycoside nephrotoxicity.

Authors:  W M Bennett; C A Wood; D C Houghton; D N Gilbert
Journal:  Am J Kidney Dis       Date:  1986-11       Impact factor: 8.860

Review 3.  Aminoglycoside research 1975-1985: prospects for development of improved agents.

Authors:  K E Price
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

4.  Postantibiotic effects.

Authors:  B S Vogelman; W A Craig
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

Review 5.  Mechanism of bactericidal action of aminoglycosides.

Authors:  B D Davis
Journal:  Microbiol Rev       Date:  1987-09

6.  Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors: 
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

7.  Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.

Authors:  S H Powell; W L Thompson; M A Luthe; R C Stern; D A Grossniklaus; D D Bloxham; D L Groden; M R Jacobs; A O DiScenna; H A Cash; J D Klinger
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

8.  Kinetics of antimicrobial activity.

Authors:  B Vogelman; W A Craig
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

9.  Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

Authors:  J E Kapusnik; C J Hackbarth; H F Chambers; T Carpenter; M A Sande
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

10.  The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure.

Authors:  W M Bennett; C E Plamp; D N Gilbert; R A Parker; G A Porter
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226
View more
  2 in total

1.  The serum vancomycin assay: A test of historic interest.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1995-03

2.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.